Several new treatments are reshaping blood sugar management, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide standing out promising candidates. Retatrutide, a dual GIP and GLP-1 receptor stimulant, shows substantial body mass decrease along with improved blood sugar regulation. Cagrillintide, one GLP-1 stimulant, is now in clinical st